Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620542 · ClinicalTrials.gov registry record · Phase 3
CRESTOR Athero Imaging Head to Head IVUS Study
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,333
- Enrollment target
NCT00620542: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00620542 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,333 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (202% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620542, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,333 participants
- Enrollment target
Study Summary
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
Primary Outcome
Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: \[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,333 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
What the finished NCT00620542 record still lists
NCT00620542 is an interventional study that assigns participants to a tested intervention. Its 2,333 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (202% higher).
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00620542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00620542 about?
NCT00620542 is a clinical study titled "CRESTOR Athero Imaging Head to Head IVUS Study". A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
What is the current status of trial NCT00620542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,333 participants. The study started on 2008-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00620542?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00620542?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00620542's enrollment target sits among peer trials
2,333 92nd of 2000 higher than 1,909 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- NCT03099850 · 2,345 participants
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia